IL5 and eosinophilic granulomatosis with polyangiitis: Because HES patients with lung involvement responded well to mepolizumab in the MHE100185 trial, and because anti-IL-5 is efficacious in severe eosinophilic asthma (which is a key feature of EGPA), it is not surprising that IL-5-targeted treatment has been tested in EGPA.